Recruiting PHASE1 INTERVENTIONAL 2-arm NCT04956068

PIPAC for Peritoneal Metastases

Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) for Peritoneal Metastases

Sponsor: National Cancer Centre, Singapore

Interventions PIPAC

Updated 5 times since 2021 Last updated: May 31, 2024 Started: May 20, 2021 Primary completion: Nov 30, 2024 Completion: Nov 30, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04956068, this PHASE1 trial focuses on Peritoneal Metastases and remains actively recruiting participants. Sponsored by National Cancer Centre, Singapore, it has been updated 5 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1

Status: Unknown Status → Recruiting
Jan 2024 — Jul 2024 [monthly]

Unknown Status PHASE1

Status: Recruiting → Unknown Status
Jan 2022 — Jan 2024 [monthly]

Recruiting PHASE1
Sep 2021 — Jan 2022 [monthly]

Recruiting PHASE1

First recorded

May 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Centre, Singapore

Data source: National Cancer Centre, Singapore

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Singapore, Singapore